
For adults with unresectable Stage 3 non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent chemoradiation therapy (CRT). See Full Indication »
When Stage 3 non-small cell lung cancer (NSCLC) cannot be removed by surgery, the first step in treatment for most patients is usually a combination of chemotherapy and radiation, called “chemoradiation therapy” or “CRT.” These can be given at the same time (concurrent). This usually lasts 6 to 7 weeks. The two treatments work in different ways to attack cancer.
attacks all fast-growing cells, including cancer cells.
targets DNA in cancer cells to keep them from growing.
If you are currently going through or have recently completed CRT, it’s important to continue working with your doctor to be prepared for what’s next. One study showed that within a year of receiving CRT, up to 89% of people progressed to Stage 4 NSCLC without further treatments.
Over the last 10 years, there have been limited advancements in treating unresectable Stage 3 NSCLC following chemoradiation therapy (CRT) given at the same time as radiation, also known as CRT. Before IMFINZI, there were no approved treatment options to help delay cancer progression in this setting. The only option was to have regular scans and check for signs of progression.
Receiving IMFINZI after CRT may help people keep fighting their unresectable Stage 3 lung cancer.
*For patients whose disease has not progressed after chemotherapy that contains platinum given at the same time as radiation therapy.
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
It is not known if IMFINZI is safe and effective in children.
Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI if you have severe side effects.
Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of IMFINZI?
IMFINZI can cause serious side effects (see above):
The most common side effects in people with non-small cell lung cancer (NSCLC) include cough, feeling tired, inflammation in the lungs, upper respiratory tract infections, shortness of breath, and rash.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
It is not known if IMFINZI is safe and effective in children.
Please click here for complete Prescribing Information, including Patient Information (Medication Guide).
IMFINZI is a medicine that may treat certain types of lung cancer by working with your immune system.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
It is not known if IMFINZI is safe and effective in children.